These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10094648)

  • 1. Bradykinin and inhibition of angiotensin-converting enzyme in hypertension.
    Azizi M
    N Engl J Med; 1999 Mar; 340(12):967; author reply 968-9. PubMed ID: 10094648
    [No Abstract]   [Full Text] [Related]  

  • 2. Bradykinin and inhibition of angiotensin-converting enzyme in hypertension.
    Agarwal R
    N Engl J Med; 1999 Mar; 340(12):967-8; author reply 968-9. PubMed ID: 10094649
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
    Gainer JV; Morrow JD; Loveland A; King DJ; Brown NJ
    N Engl J Med; 1998 Oct; 339(18):1285-92. PubMed ID: 9791144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    Lebel M; Rodrigue ME; Agharazii M; Larivière R
    Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormonal contribution to short-term variability of blood pressure in a renovascular hypertension model].
    Ponchon P; Elghozi JL
    Arch Mal Coeur Vaiss; 1995 Aug; 88(8):1203-7. PubMed ID: 8572874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
    Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure responses to acute or chronic captopril in mice with disruption of bradykinin B2-receptor gene.
    Emanueli C; Angioni GR; Anania V; Spissu A; Madeddu P
    J Hypertens; 1997 Dec; 15(12 Pt 2):1701-6. PubMed ID: 9488225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme and angiotensin II receptor subtype 1 inhibitors restitute hypertensive internal anal sphincter in the spontaneously hypertensive rats.
    De Godoy MA; Rattan S
    J Pharmacol Exp Ther; 2006 Aug; 318(2):725-34. PubMed ID: 16648368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of angiotensin receptor antagonists and angiotensin converting enzyme inhibitors in arterial hypertension].
    Krezsinski JM; Sternon J
    Rev Med Brux; 2000 Jun; 21(3):170-7. PubMed ID: 10925600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity.
    Zusman RM
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):13-23. PubMed ID: 3037886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors: pathogenic and therapeutic implications for arterial hypertension.
    Waeber B; Brunner HR; Wauters JP; Gavras H
    Adv Nephrol Necker Hosp; 1981; 10():111-33. PubMed ID: 6267906
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacology of ACE inhibitors versus AT1 blockers.
    Vaughan D
    Can J Cardiol; 2000 Aug; 16 Suppl E():36E-40E. PubMed ID: 10906625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiotensin converting enzyme inhibitors--a new group of hypotensive drugs].
    Lazowski J
    Wiad Lek; 1984 May; 37(10):792-6. PubMed ID: 6095537
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and aldosterone in essential hypertension].
    Posadas C; Sánchez G; Boyer JL; Delmar M; Serrano PA
    Arch Inst Cardiol Mex; 1982; 52(4):295-300. PubMed ID: 6291470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations].
    Andréjak M; Slama M; Hary L
    Therapie; 1998; 53(3):291-300. PubMed ID: 9773129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bradykinin and inhibition of angiotensin-converting enzyme in hypertension.
    Gallois H; Piot O
    N Engl J Med; 1999 Mar; 340(12):968-9. PubMed ID: 10094650
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors in hypertension: a review.
    Salvetti A; Pedrinelli R; Arzilli F; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
    Int J Clin Pharmacol Res; 1985; 5(6):429-38. PubMed ID: 3005182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive drug management of hypertension.
    Oparil S; Winternitz S
    Cardiovasc Clin; 1984; 14(3):73-91. PubMed ID: 6144392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.